Schedule III opens the federal door, but the DEA decides who can cross it.

For years, one of the big questions surrounding cannabis in the United States was when its classification would change under federal law.

Now, for medicinal cannabis subject to state licenses, that question already has an answer.

In April 2026, the Department of Justice placed both FDA-approved cannabis products and cannabis subject to certain state medical licenses on Schedule III . This measure did not make cannabis a legal substance without federal restrictions. On the contrary, it opened the door to a new framework of federal oversight.

And on October 5th came one of the most concrete steps in that new scenario.

The DEA's Diversion Control Division opened the registration process using DEA Form 225 for medical cannabis companies that manufacture, process, grow, distribute, or perform laboratory testing.

The difference may seem bureaucratic.

It isn't.

From reclassification to compliance

Schedule III does not simply represent a different label.

For an industry that for decades has operated in a zone of tension between state laws and federal prohibition, the new classification begins to create a structure in which the federal government recognizes certain activities related to medicinal cannabis, but requires those who carry them out to also enter into its control system.

That is the true meaning of Form 225.

The registration process requests personal and business information, the company's activities, state licenses, background information and potential regulatory actions, as well as the corresponding payment.

In other words: state licensing remains essential, but it no longer tells the whole story.

The federal rule establishes a registration mechanism for entities with state medical cannabis licenses and stipulates that the state license serves as evidence of authorization under state law. At the same time, the DEA retains public interest and federal compliance criteria that must be considered.

It's a kind of bridge.

But the bridge has a toll and checkpoints.

The incentive that can change the equation

One of the biggest attractions of Schedule III is outside the plant and inside the accounting books.

Section 280E of the Internal Revenue Code limits ordinary deductions for businesses that traffic in Schedule I or II substances. By moving the medicinal cannabis covered by the new rule to Schedule III, that specific obstacle associated with 280E for those activities disappears.

For an industry that has had to operate for years with a particularly heavy tax structure, the change can have significant consequences for profitability, cash flow, and investment.

But this is where it's best to tone down the celebration.

Schedule III does not mean full federal legalization of cannabis.

The federal government itself maintains controls over these substances and continues a separate process to determine whether marijuana in broader terms should be moved to Schedule III.

The distinction matters.

A lot.

The DEA also wants to know who is behind the business.

The new process sends another clear signal: the next stage of medicinal cannabis will also be a stage of greater corporate scrutiny .

The form asks about convictions related to controlled substances, revoked or suspended federal registrations, state professional licenses, and other regulatory actions.

If the answer is yes, the applicant must provide additional information about what happened.

This changes the conversation.

The industry no longer only has to demonstrate that it has a license to operate. In the new federal context, it will have to demonstrate that it can integrate into a system designed around the control, traceability, and prevention of substance diversion.

And that makes sense within the logic used by the government.

The April order explained that incorporating state licensing systems into the federal framework was, according to the Justice Department's determination, a way to meet U.S. obligations under the United Nations Single Convention on Narcotic Drugs , while maintaining medical access and reducing disruption to existing state systems.

The industry, therefore, is entering into a different relationship with Washington.

Not necessarily simpler.

But it is more defined.

The cost of entry also counts.

Registration is not free either.

According to information published for Form 225, the non-refundable annual fees are $3,699 for manufacturers, $1,850 for distributors, and $296 for analytical labs .

For an established company, it can be an additional operating cost.

For a small company, it can represent another barrier.

And there's an irony that's hard to ignore.

The new process allows electronic payments using cards such as Visa, Mastercard, American Express, or Discover, while the card networks themselves have maintained restrictions related to cannabis transactions.

It is a contradiction that sums up much of the history of this industry:

Regulation can change faster than the financial infrastructure that surrounds it.

The new question

For a long time, the industry asked:

When will the federal status of medical cannabis change?

Now the question is different:

What does it really mean to operate within that new status?

Schedule III can open economic opportunities, reduce a historic tax burden, and provide federal recognition for the medical use of certain state products and programs.

But it also brings with it records, fees, background checks, controls, obligations, and a much more direct relationship with the DEA.

The federal door opened.

Now the most complicated part begins:

learn to operate on the other side of it.

And perhaps that is the true story of Schedule III.

Not the end of cannabis regulation.

The beginning of a new stage of compliance.

Important editorial note

To avoid a very common misconception, this piece should clarify that the current change pertains to medical cannabis covered by the federal order , not to a general federal legalization of adult cannabis. The broader marijuana rescheduling process continues through a separate administrative route.